Monitoring of Anti-L-Asparaginase Antibody and L-Asparaginase Activity Levels in a Pediatric Patient With Acute Lymphoblastic Leukemia and Hypersensitivity to Native Escherichia coli L-Asparaginase During Desensitization Courses

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of pediatric hematology/oncology

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MPH.0b013e3182986559PMID 23689289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.

  2012cited by this paper
• Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.

  2011cited by this paper
• L‐asparaginase treatment in acute lymphoblastic leukemia

  2011cited by this paper
• A Desensitization Protocol in Children With L-Asparaginase Hypersensitivity

  2010cited by this paper
• Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia

  2010cited by this paper
• The ex vivo production of ammonia predicts l-asparaginase biological activity in children with acute lymphoblastic leukemia

  2009cited by this paper
• Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.

  2009cited by this paper
• Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group Study L99-15

  2008cited by this paper
• Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial.

  2008cited by this paper
• The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

  2007cited by this paper
• Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

  2007cited by this paper
• Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia

  2004cited by this paper
• Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961

  2004cited by this paper
• l-Asparagine depletion levels and l-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment

  2004cited by this paper
• Development of anti‐asparaginase antibodies in childhood acute lymphoblastic leukemia

  2004cited by this paper
• Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

  2003cited by this paper
• L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.

  2000cited by this paper
• Rapid desensitization for L-asparaginase hypersensitivity.

  1998cited by this paper
• Use of L-asparaginase in childhood ALL.

  1998cited by this paper
• Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

  1998cited by this paper
• [Improved measurements of anti-L-asparaginase IgG antibody and its clinical applications].

  1992cited by this paper
• L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.

  1981cited by this paper

• Silent inactivation of asparaginase in Japan: results of the prospective ALL-ASP19 trial

  2024cites this paper
• Acute complications observed during intensive chemotherapy in pediatric patients with acute lymphoblastic leukemia: Single-center experience

  2023cites this paper
• l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

  2023cites this paper
• Pterostilbene Enhances Anticancer Effects of L-asparaginase in Lymphoblastic Leukemia Cell Line

  2019cites this paper
• Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia

  2017cites this paper
• Asparaginase-associated toxicity in children with acute lymphoblastic leukemia

  2015cites this paper
• Clinical application of asparaginase activity levels following treatment with pegaspargase

  2015cites this paper
• Efficacy and Toxicity of Asparaginases During Prospective Drug Monitoring in Patients With Childhood Acute Lymphoblastic Leukemia

  2014cites this paper
• Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase

  2014cites this paper
• Anaphylactic reaction to polyethylene glycol‐conjugated asparaginase: Premedication and desensitization may not be sufficient

  2014cites this paper